The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
10.1186/s40880-015-0010-1
- Author:
Richard E KAST
1
Author Information
1. International Initiative for Accelerated Improvement of Glioblastoma Care Study Center, 22 Church Street, Burlington, VT, 05401, USA. richarderickast@gmail.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Dacarbazine;
analogs & derivatives;
Disulfiram;
Glioblastoma;
Humans;
Interleukin-18;
Ritonavir
- From:Chinese Journal of Cancer
2015;34(4):161-165
- CountryChina
- Language:English
-
Abstract:
Based on reporting in the last several years, an impressive but dismal list of cytotoxic chemotherapies that fail to prolong the median overall survival of patients with glioblastoma has prompted the development of treatment protocols designed to interfere with growth-facilitating signaling systems by using non-cytotoxic, non-oncology drugs. Recent recognition of the pro-mobility stimulus, interleukin-18, as a driver of centrifugal glioblastoma cell migration allows potential treatment adjuncts with disulfiram and ritonavir. Disulfiram and ritonavir are well-tolerated, non-cytotoxic, non-oncology chemotherapeutic drugs that are marketed for the treatment of alcoholism and human immunodeficiency virus (HIV) infection, respectively. Both drugs exhibit an interleukin-18-inhibiting function. Given the favorable tolerability profile of disulfiram and ritonavir, the unlikely drug-drug interaction with temozolomide, and the poor prognosis of glioblastoma, trials of addition of disulfiram and ritonavir to current standard initial treatment of glioblastoma would be warranted.
